Page 2 - Nyse Ikt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nyse ikt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nyse Ikt Today - Breaking & Trending Today
Inhibikase Therapeutics (NYSE:IKT – Get Rating) and Genfit (NASDAQ:GNFT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Risk and Volatility Inhibikase Therapeutics has a beta of 0.94, […] ....
HC Wainwright reaffirmed their buy rating on shares of Inhibikase Therapeutics (NYSE:IKT – Get Rating) in a research note released on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q1 2023 earnings at ($0.15) EPS, Q2 2023 earnings at ($0.16) EPS, Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings […] ....
Inhibikase Therapeutics (NYSE:IKT – Get Rating) is set to announce its earnings results after the market closes on Friday, March 31st. Inhibikase Therapeutics Stock Performance Shares of NYSE IKT opened at $0.72 on Friday. The company has a market capitalization of $20.06 million, a P/E ratio of -0.97 and a beta of 0.98. Inhibikase Therapeutics […] ....
Inhibikase Therapeutics (NYSE:IKT – Get Rating) will be releasing its earnings data after the market closes on Thursday, March 31st. Persons that wish to register for the company’s earnings conference call can do so using this link. Shares of Inhibikase Therapeutics stock opened at $1.35 on Tuesday. The stock has a market capitalization of $33.99 […] ....
Inhibikase Therapeutics (NYSE:IKT – Get Rating) and Osiris Therapeutics (OTCMKTS:OSIR – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Profitability This table compares Inhibikase Therapeutics and Osiris Therapeutics’ […] ....